These programmes, also called Early Access Programmes, make investigational drugs available for the treatment of serious life-threatening disease to people for whom treatment options are limited.
These programmes, also called Early Access Programmes, make investigational drugs available for the treatment of serious life-threatening disease to people for whom treatment options are limited.